Literature DB >> 9808601

Nonsustained ventricular tachycardia in the setting of acute myocardial infarction: tachycardia characteristics and their prognostic implications.

A N Cheema1, K Sheu, M Parker, A H Kadish, J J Goldberger.   

Abstract

BACKGROUND: Nonsustained ventricular tachycardia (NSVT) has significant prognostic implications in the setting of healing and healed myocardial infarction (MI), but only limited information is available on its importance in the setting of acute MI. We evaluated the prognostic significance of NSVT characteristics in the setting of acute MI. METHODS AND
RESULTS: A prospective database was used to identify 112 patients with NSVT within 72 hours of acute MI. A control group was identified matched for age, sex, type of MI, and thrombolytic treatment. Mean age was 64 to 65 years in the 2 groups with 71% to 72% men. Q-wave MI was noted in 52% to 53%, and thrombolytic therapy was administered to 31% to 32% of patients in each group. In-hospital ventricular fibrillation occurred more frequently in the NSVT group (9% versus 0% in the control group; P<0. 001), but total in-hospital (10% versus 4%) and follow-up mortality (10% versus 17%) did not differ between the 2 groups. With a Cox regression model, specific NSVT characteristics were predictive of mortality. The strongest predictor was time from presentation to occurrence of NSVT. Shortest RR interval during NSVT was also a univariate predictor of mortality. Multivariate analysis identified time from presentation to occurrence of NSVT as the strongest predictor of mortality (P<0.0001). The increased relative risk of NSVT was first significant when it occurred 13 hours from presentation and continued to increase as the time from presentation to occurrence of NSVT increased, plateauing at approximately 24 hours with a relative risk of 7.5.
CONCLUSIONS: Contrary to prevailing clinical opinion, NSVT that occurs in the setting of acute MI does have important prognostic significance. Specifically, the currently accepted notion that NSVT that occurs within 48 hours of acute MI has no prognostic significance needs to be adjusted. Although NSVT that occurs within the first several hours of presentation does not have an associated adverse prognosis, NSVT that occurs beyond the first several hours after presentation is associated with significant increases in relative risk.

Entities:  

Mesh:

Year:  1998        PMID: 9808601     DOI: 10.1161/01.cir.98.19.2030

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

1.  Effect of supplemented intake of omega-3 fatty acids on arrhythmias in patients with ICD: fish oil therapy may reduce ventricular arrhythmia.

Authors:  Dalit Weisman; Roy Beinart; Aharon Erez; Nira Koren-Morag; Ilan Goldenberg; Michael Eldar; Michael Glikson; David Luria
Journal:  J Interv Card Electrophysiol       Date:  2017-06-29       Impact factor: 1.900

2.  Effects of rosuvastatin and atorvastatin on nonsustained ventricular tachycardia in patients with ST-elevation myocardial infarction: a retrospective analysis.

Authors:  Xianqing Hu; Jian Cheng; Chunjian Li
Journal:  Eur J Clin Pharmacol       Date:  2017-09-30       Impact factor: 2.953

3.  2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry.

Authors:  Jonathan S Steinberg; Niraj Varma; Iwona Cygankiewicz; Peter Aziz; Paweł Balsam; Adrian Baranchuk; Daniel J Cantillon; Polychronis Dilaveris; Sergio J Dubner; Nabil El-Sherif; Jaroslaw Krol; Malgorzata Kurpesa; Maria Teresa La Rovere; Suave S Lobodzinski; Emanuela T Locati; Suneet Mittal; Brian Olshansky; Ewa Piotrowicz; Leslie Saxon; Peter H Stone; Larisa Tereshchenko; Mintu P Turakhia; Gioia Turitto; Neil J Wimmer; Richard L Verrier; Wojciech Zareba; Ryszard Piotrowicz
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-05       Impact factor: 1.468

4.  Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).

Authors:  Jay Chen; George Johnson; Anne S Hellkamp; Jill Anderson; Daniel B Mark; Kerry L Lee; Gust H Bardy; Jeanne E Poole
Journal:  J Am Coll Cardiol       Date:  2013-03-26       Impact factor: 24.094

5.  beta-Blocker use following myocardial infarction: low prevalence of evidence-based dosing.

Authors:  Jeffrey J Goldberger; Robert O Bonow; Michael Cuffe; Alan Dyer; Yves Rosenberg; Robert O'Rourke; Prediman K Shah; Sidney C Smith
Journal:  Am Heart J       Date:  2010-09       Impact factor: 4.749

Review 6.  Nonsustained ventricular tachycardia in dilated cardiomyopathy.

Authors:  Frank A Cuoco; Steven N Singh
Journal:  Curr Cardiol Rep       Date:  2005-09       Impact factor: 2.931

7.  The persistent sodium current blocker riluzole is antiarrhythmic and anti-ischaemic in a pig model of acute myocardial infarction.

Authors:  Steven M Weiss; David A Saint
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

8.  Prognostic significance of nonsustained ventricular tachycardia in patients receiving cardiac resynchronization therapy for primary prevention: Analysis of the Japan cardiac device treatment registry database.

Authors:  Hisashi Yokoshiki; Akihiko Shimizu; Takeshi Mitsuhashi; Hiroshi Furushima; Yukio Sekiguchi; Tetsuyuki Manaka; Nobuhiro Nishii; Takeshi Ueyama; Norishige Morita; Hideo Okamura; Takashi Nitta; Kenzo Hirao; Ken Okumura
Journal:  J Arrhythm       Date:  2018-01-12

Review 9.  How to manage various arrhythmias and sudden cardiac death in the cardiovascular intensive care.

Authors:  Yoshinori Kobayashi
Journal:  J Intensive Care       Date:  2018-04-11

10.  Prognostic significance of non-sustained ventricular tachycardia on stored electrograms in pacemaker recipients.

Authors:  Gianluigi Bencardino; Francesco Raffaele Spera; Gaetano Pinnacchio; Francesco Perna; Maria Lucia Narducci; Gianluca Comerci; Gemma Pelargonio; Francesca Augusta Gabrielli; Giulio La Rosa; Gaetano Antonio Lanza; Filippo Crea
Journal:  PLoS One       Date:  2019-11-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.